Dabur says India business is unaffected by USFDA warning at Silvassa plant

Dabur said its Silvassa pharmaceutical facility remains operational despite a USFDA warning citing CGMP and data-integrity deficiencies. The company is implementing corrective actions, has shifted some production to Baddi and says the issue does not affect its India business.

— Source publishedThu, 6 Aug, 2026, 22:44 IST·First seen Thu, 6 Aug, 2026, 22:49 IST·Source Mint

What happened

Dabur India · Dabur said its India business is unaffected by a USFDA warning over CGMP and data-integrity deficiencies at its Silvassa pharmaceutical plant. The

Key facts

  • 15 working days
  • June 2, 2026
  • June 5, 2026
  • May 13, 2026
  • July 24, 2027

Why this matters

Any partnership or acquisition involving Dabur’s pharma assets should include heightened diligence on CGMP controls, data integrity, and remediation progress.

What to watch

  • USFDA acceptance, rejection or follow-up queries on Dabur's corrective action response.
  • Any import alert, product detention, recall or restriction linked to the Silvassa facility.
  • Disclosure of Silvassa-linked export revenue, inventory write-downs, remediation expenses or capacity constraints.
  • Duration and scale of production moved to Baddi, including approval and validation status.
  • New inspection observations at Silvassa or other Dabur pharma/healthcare plants.
  • Submit and execute a time-bound corrective and preventive action plan addressing CGMP and data-integrity observations.
  • Shift critical volumes to Baddi or qualified alternate sites while completing validation and regulatory documentation.
  • Increase quality-system audits, electronic data controls and third-party compliance oversight across pharmaceutical facilities.
  • Provide investor updates on affected export revenue, remediation costs, production transfers and USFDA correspondence.

Also reported by